Non - surgical treatment of squint i.e. all types of squint have some modalities of treatment [ optical treatment, orthoptic treatment, Prismo-therapy, and pharmacological treatment] except surgical treatment.
1. OPTICAL TREATMENT -
in optical treatment, it should be include correction of refractive error and prismotherapy.
SPECTACLES should be prescribed in every cases.
It may correct to squint partially or completely.
IN PRISMOTHERAPY, for correction of squint, This is light weight, and easy to apply on the back surface of glass.
It is useful in heterophoria, nystagmus, convergence insufficiency, managing diplopia and maintain binocular single vision.
IN PHARMACOLOGICAL TREATMENT, miotics, atropine and botulinum toxin are prescribed in some types of cases of strabismus.
IN ORTHOPTIC TREATMENT, means straight eyes.
It is used as a diagnostic purpose and therapeutic purposes.
- to increase fusion amplitude.
- anti suppression exercises.
- treatment of amblyopia.
- treatment of abnormal retinal correspondance.
- to control deviations.
ORDER OF ORHOPTIC TREATMENT -
. amblyopia is treated firstly.
. anti- suppression therapy.
- diplopia training.
- amplitude improvement.
Non - surgical treatment of squint i.e. all types of squint have some modalities of treatment [ optical treatment, orthoptic treatment, Prismo-therapy, and pharmacological treatment] except surgical treatment.
1. OPTICAL TREATMENT -
in optical treatment, it should be include correction of refractive error and prismotherapy.
SPECTACLES should be prescribed in every cases.
It may correct to squint partially or completely.
IN PRISMOTHERAPY, for correction of squint, This is light weight, and easy to apply on the back surface of glass.
It is useful in heterophoria, nystagmus, convergence insufficiency, managing diplopia and maintain binocular single vision.
IN PHARMACOLOGICAL TREATMENT, miotics, atropine and botulinum toxin are prescribed in some types of cases of strabismus.
IN ORTHOPTIC TREATMENT, means straight eyes.
It is used as a diagnostic purpose and therapeutic purposes.
- to increase fusion amplitude.
- anti suppression exercises.
- treatment of amblyopia.
- treatment of abnormal retinal correspondance.
- to control deviations.
ORDER OF ORHOPTIC TREATMENT -
. amblyopia is treated firstly.
. anti- suppression therapy.
- diplopia training.
- amplitude improvement.
A detailed presentation covering all aspects of amblyopia, a form of cortical visual impairment, defined clinically as a unilateral or bilateral decrease of visual acuity (VA) that cannot be attributed to structural abnormalities of the eye or visual pathway
A detailed presentation covering all aspects of amblyopia, a form of cortical visual impairment, defined clinically as a unilateral or bilateral decrease of visual acuity (VA) that cannot be attributed to structural abnormalities of the eye or visual pathway
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The